Uncovering misconceptions about asthma Published: 11:17 PM, May 22, 2021 Although asthma is not curable, it is possible to gain complete control over it and lead a normal active life
Untitled-1 SHARE
In these unprecedented times, the burden of lung diseases has increased manifold. As we are fighting against the global pandemic, people are getting hit by a great deal of misinformation and misconceptions around lung health, and especially so in the case of asthma. As World Asthma Day was marked recently (May 5), the most important point noted by experts was the need to come together to dispel the myths and fears regarding asthma and encourage those affected by this condition to live a healthy life.
This meta-analysis of 20 randomized trials reported in 6 clinical databases compares outcomes associated with dual therapy of inhaled corticosteroids (ICS) and
Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
05/17/2021 | 06:01am EDT
Send by mail :
Message :
Dexpramipexole was well tolerated, with 97% of drug-treated patients completing the primary assessment phase
Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma. The data were presented in a virtual poster session at the ATS 2021 International Conference.
The EXHALE trial was a randomized, double-blind, placebo-controlled study of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) ≥300/µL. Dexpramipexole study drug at oral doses of 75 mg/day, 150 mg/day, or 300 mg/day was added to standard of care. The primary endpoint was change in AEC from Baseline to Week 12 compared to placeb